Astellas has promoted Lei Ding to VP of payer strategy, contracts, and pricing.

She will oversee these three areas for Astellas’ U.S. business, reporting to Shontelle Dodson, SVP of health systems.

Previously, Ding served as executive director of contracts and pricing. Over her nine years at Astellas, she has held several roles in pricing and contracting. Before joining Astellas, Ding was senior manager of planning and portfolio analysis at Takeda and group manager of forecasting and commercial planning at TAP Pharmaceuticals.

Earlier this year, Astellas faced drug pricing scrutiny after a report suggested its prostate cancer drug Xtandi was overpriced. The drugmaker rejected the assertion, saying the U.K.’s drug watchdog determined the price was acceptable and that many patients did not pay full price for the treatment.

This year, Astellas also named Colin McBean senior director of product and brand communications, overseeing all product communications and Astellas branding in the Americas.

The Japanese pharma company also saw the departure of its communications and corporate affairs head Jeff Winton this summer. Winton joined Boston-based pharma company Alkermes as SVP of public affairs. At Astellas, Moyra Knight was promoted to head up the communications function.